Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"
2020 ◽
2020 ◽
Inhibition of fatty acid synthase with
FT‐4101
safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
2020 ◽
